SOPHiA GENETICS and Exactis Innovation form collaboration to progress cancer research and patient care through real-world data
SOPHiA GENETICS, a cloud-native software company specializing in data-driven medicine, has announced a collaboration with Exactis Innovation, a non-profit network of hospital partners across Canada. The partnership is focused on contributing to cancer research and enhancing data-driven decision-making through SOPHiA GENETICS’ multimodal real-world data (RWD) offering.
Exactis Innovation, who are committed to improving cancer survivorship by accelerating data-driven decision-making, will join the SOPHiA DDM™ network, giving them access to the SOPHiA DDM™ platform. This will enable them to derive insights from global RWD across diverse datasets, aligning with Exactis’ mission to harness collective intelligence and impartial insights to support research.
“Our enhanced focus on real-world data positions us as a key resource for impartial insights for both industry and public sectors. Our participation in contributing to, and learning from, the collective intelligence enabled by SOPHiA GENETICS stems from our belief that the path to superior data-driven decisions lies in overcoming borders and utilizing top-tier, ready-to-use real world data,” stated Kostas Trakas, CEO of Exactis Innovation.
Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, highlighted the aim of improving health outcomes globally by empowering local health institutions with the technology needed for data-driven medicine, saying, “As health data consumption grows and becomes increasingly complex and multifaceted, it is imperative that healthcare organizations have the ability to process data in a timely manner and receive highly accurate results. SOPHiA GENETICS and Exactis Innovation have the shared vision to improve cancer survivorship in Canada by unlocking insights from medical data and contributing to a global collective intelligence”. The collaboration aims to process health data in a timely manner, providing highly accurate results in the face of growing complexity and multifaceted health data consumption.
The collaboration expands Exactis’ testing capabilities with advanced cancer testing solutions including MSK-ACCESS® and MSK-IMPACT®, powered by SOPHiA DDM™ and HRD testing. The SOPHiA DDM™ Platform will support Exactis in increasing the volume and speed of next-generation sequencing testing and tumor profiling, ultimately optimizing care decisions and treatment strategies.
Gerald Batist, MD, Chief Medical Officer of Exactis Innovation and Director of the Segal Cancer Centre at the Jewish General Hospital, spoke of the transformative impact of the partnership. He stated, “Our collaboration with SOPHiA GENETICS empowers us with advanced tools, enhancing our capabilities in data-driven medicine. This partnership places Canadians at the forefront of a global initiative, leveraging real world data to elevate patient care, inform critical health decisions, and foster groundbreaking discoveries”.
Exactis leads Canada’s most extensive pan-cancer research initiative with nearly 10,000 patients across 16 cancer sites. This collaboration with SOPHiA GENETICS will further strengthen Exactis’s capabilities in data-driven medicine, providing advanced tools for groundbreaking discoveries. The collaboration signifies a collective effort to leverage RWD for the betterment of global health outcomes, with Canadians at the forefront of this impactful initiative.
You may also be interested in:
Want regular updates on the latest real-world evidence news straight to your inbox? Become a member on The Evidence Base® today>>>
